Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | jmjC domain containing protein | 0.0096 | 0.4766 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.0473 | 0.5 |
Giardia lamblia | PHD finger protein 15 | 0.0029 | 0 | 0.5 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0036 | 0.0441 | 0.1625 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.117 | 0.117 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.144 | 0.5311 |
Schistosoma mansoni | hypothetical protein | 0.017 | 1 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.005 | 0.144 | 0.3022 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.117 | 0.117 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0067 | 0.2712 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0067 | 0.2712 | 0.2712 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0067 | 0.2712 | 0.2712 |
Echinococcus multilocularis | geminin | 0.017 | 1 | 1 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0036 | 0.0441 | 0.0441 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.0473 | 0.0473 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0046 | 0.117 | 0.4315 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0036 | 0.0473 | 0.0473 |
Loa Loa (eye worm) | hypothetical protein | 0.0067 | 0.2712 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.0473 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0036 | 0.0473 | 0.0473 |
Echinococcus multilocularis | acetylcholinesterase | 0.0067 | 0.2712 | 0.2712 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0036 | 0.0441 | 0.0441 |
Schistosoma mansoni | hypothetical protein | 0.0034 | 0.0322 | 0.0322 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0061 | 0.223 | 0.8224 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.117 | 0.117 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.005 | 0.144 | 0.3022 |
Brugia malayi | Carboxylesterase family protein | 0.0067 | 0.2712 | 0.5691 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0036 | 0.0441 | 0.0441 |
Plasmodium falciparum | phd finger protein, putative | 0.0029 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0067 | 0.2712 | 0.2712 |
Brugia malayi | Carboxylesterase family protein | 0.0067 | 0.2712 | 0.5691 |
Plasmodium vivax | hypothetical protein, conserved | 0.0029 | 0 | 0.5 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0096 | 0.4766 | 0.4766 |
Echinococcus multilocularis | jumonji domain containing protein | 0.0041 | 0.082 | 0.082 |
Echinococcus granulosus | carboxylesterase 5A | 0.0067 | 0.2712 | 0.2712 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.005 | 0.144 | 0.5311 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0036 | 0.0473 | 0.0473 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.117 | 0.117 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0322 | 0.1186 |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0036 | 0.0441 | 0.0441 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.1496 | 0.5518 |
Schistosoma mansoni | hypothetical protein | 0.017 | 1 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0034 | 0.0322 | 0.0675 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0096 | 0.4766 | 0.4766 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.117 | 0.117 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0029 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0067 | 0.2712 | 1 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0029 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.0473 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0067 | 0.2712 | 0.2712 |
Loa Loa (eye worm) | carboxylesterase | 0.0067 | 0.2712 | 1 |
Schistosoma mansoni | jumonji domain containing protein | 0.0076 | 0.3356 | 0.3356 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.117 | 0.117 |
Brugia malayi | jmjC domain containing protein | 0.0036 | 0.0441 | 0.0925 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0046 | 0.117 | 0.2455 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0067 | 0.2712 | 0.2712 |
Brugia malayi | hypothetical protein | 0.0036 | 0.0473 | 0.0993 |
Onchocerca volvulus | Alhambra homolog | 0.0029 | 0 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.117 | 0.117 |
Echinococcus granulosus | jumonji domain containing protein | 0.0041 | 0.082 | 0.082 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.0473 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0.77 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 2 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 3.72 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 3.88 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 24 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 85 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 99 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 14.29 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 2 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 24 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 85 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 99 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.17 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.67303 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.